- Home
- KYMR vs CPRI Comparison
KYMR vs CPRI Comparison
Compare KYMR & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYMR
- CPRI
- Stock Information
- Founded
- KYMR 2015
- CPRI 1981
- Country
- KYMR United States
- CPRI United Kingdom
- Employees
- KYMR N/A
- CPRI N/A
- Industry
- KYMR Medicinal Chemicals and Botanical Products
- CPRI Apparel
- Sector
- KYMR Health Care
- CPRI Consumer Discretionary
- Exchange
- KYMR Nasdaq
- CPRI Nasdaq
- Market Cap
- KYMR 2.6B
- CPRI 2.6B
- IPO Year
- KYMR 2020
- CPRI 2011
- Fundamental
- Price
- KYMR $40.61
- CPRI $23.81
- Analyst Decision
- KYMR Buy
- CPRI Buy
- Analyst Count
- KYMR 15
- CPRI 11
- Target Price
- KYMR $55.60
- CPRI $27.55
- AVG Volume (30 Days)
- KYMR 532.1K
- CPRI 2.8M
- Earning Date
- KYMR 02-20-2025
- CPRI 02-05-2025
- Dividend Yield
- KYMR N/A
- CPRI N/A
- EPS Growth
- KYMR N/A
- CPRI N/A
- EPS
- KYMR N/A
- CPRI N/A
- Revenue
- KYMR $87,563,000.00
- CPRI $4,796,000,000.00
- Revenue This Year
- KYMR N/A
- CPRI N/A
- Revenue Next Year
- KYMR $33.16
- CPRI $0.76
- P/E Ratio
- KYMR N/A
- CPRI N/A
- Revenue Growth
- KYMR 86.92
- CPRI N/A
- 52 Week Low
- KYMR $26.92
- CPRI $18.70
- 52 Week High
- KYMR $53.27
- CPRI $50.62
- Technical
- Relative Strength Index (RSI)
- KYMR 47.90
- CPRI 60.19
- Support Level
- KYMR $40.20
- CPRI $22.76
- Resistance Level
- KYMR $44.34
- CPRI $24.08
- Average True Range (ATR)
- KYMR 2.58
- CPRI 0.83
- MACD
- KYMR 0.29
- CPRI 0.39
- Stochastic Oscillator
- KYMR 57.47
- CPRI 83.60
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
About CPRI Capri Holdings Limited
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.